Likelihood of stopping anabolic–androgenic steroids in next 5 years | Respondents, n = 470 (%) |
 1 (Very unlikely) | 135 (28.7) |
 2 | 138 (29.4) |
 3 | 96 (20.4) |
 4 | 48 (10.2) |
 5 (Very likely) | 53 (11.3) |
Worries about stopping anabolic–androgenic steroids | Respondents, n = 443 (%) |
 Nothing | 82 (18.5) |
 Recovery of testosterone or fertility | 232 (52.4) |
 Effects on body composition or physical performance | 268 (60.5) |
 Access to NHS for advice | 107 (24.2) |
 Quality of NHS advice | 110 (24.8) |
 Effectiveness or purity of PCT | 182 (41.1) |
 Other | 20 (4.5) |
Interest in participating in a research trial about post-cycle therapy | Respondents, n = 469 (%) |
 1 (Not at all interested) | 156 (33.3) |
 2 | 76 (16.2) |
 3 | 92 (19.6) |
 4 | 42 (9.0) |
 5 (Very interested) | 103 (22.0) |
Where would be best to access National Health Service (NHS) prescribed post-cycle therapy? | Respondents, n = 470 (%) |
 Community e.g., harm prevention clinic or local pharmacy | 206 (43.8) |
 GP surgery | 109 (23.2) |
 NHS Specialist clinic e.g., endocrinology | 47 (10.0) |
 Online service | 138 (29.4) |